Credit Suisse’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-22,966
| Closed | -$343K | – | 3972 |
|
|
2022
Q4 | $343K | Buy |
+22,966
| New | +$318K | ﹤0.01% | 2968 |
|
|
2019
Q3 | – | Sell |
-2,244
| Closed | -$16K | – | 4339 |
|
|
2019
Q2 | $16K | Sell |
2,244
-332
| -13% | -$2.84K | ﹤0.01% | 4052 |
|
|
2019
Q1 | $21K | Buy |
2,576
+714
| +38% | +$7.37K | ﹤0.01% | 3939 |
|
|
2018
Q4 | $30K | Buy |
+1,862
| New | +$41K | ﹤0.01% | 3826 |
|
|
2018
Q3 | – | Sell |
-2,840
| Closed | -$65K | – | 4106 |
|
|
2018
Q2 | $65K | Buy |
2,840
+1,193
| +72% | +$28.3K | ﹤0.01% | 3879 |
|
|
2018
Q1 | $48K | Sell |
1,647
-885
| -35% | -$25.9K | ﹤0.01% | 3885 |
|
|
2017
Q4 | $70K | Buy |
+2,532
| New | +$78.6K | ﹤0.01% | 3884 |
|
|
2015
Q1 | – | Sell |
-3,468
| Closed | -$29K | – | 4677 |
|
|
2014
Q4 | $29K | Buy |
+3,468
| New | +$31.7K | ﹤0.01% | 4537 |
|
|
2014
Q3 | – | Sell |
-6,607
| Closed | -$121K | – | 4745 |
|
|
2014
Q2 | $121K | Buy |
6,607
+3,739
| +130% | +$48.6K | ﹤0.01% | 4502 |
|
|
2014
Q1 | $43K | Sell |
2,868
-5,154
| -64% | -$92.6K | ﹤0.01% | 4584 |
|
|
2013
Q4 | $147K | Buy |
8,022
+3,734
| +87% | +$74.8K | ﹤0.01% | 4405 |
|
|
2013
Q3 | $88K | Sell |
4,288
-79,815
| -95% | -$1.83M | ﹤0.01% | 4125 |
|
|
2013
Q2 | $2.1M | Buy |
+84,103
| New | +$3.6M | ﹤0.01% | 2228 |
|
Credit Suisse's AVEO Position: Q1 2023 in Review
Credit Suisse sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 22,966 shares — an estimated $343K sold.
Credit Suisse first reported a position in AVEO in Q2 2013 and held it in 13 quarters. The position peaked at $2.1M in Q2 2013. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Credit Suisse reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Credit Suisse sold 22,966 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $343K.
- Credit Suisse first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
- Credit Suisse's AVEO Pharmaceuticals, Inc. position peaked at $2.1M in Q2 2013.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.